Characterization of synergistic induction of CX3CL1/fractalkine by TNF-α and IFN-γ in vascular endothelial cells: An essential role for TNF-α in post-transcriptional regulation of CX3CL1

Journal of Immunology

Volumn 184, Issue 8, 2010, Pages 4205-4214

  Matsumiya, Tomoh ^a   Ota, Ken ^b   Imaizumi, Tadaatsu ^a   Yoshida, Hidemi ^a   Kimura, Hiroto ^a   Satoh, Kei ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FRACTALKINE; GAMMA INTERFERON; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; TUMOR NECROSIS FACTOR ALPHA; CX3CL1 PROTEIN, HUMAN; ELAV-LIKE PROTEIN 1; HUR PROTEIN; MEMBRANE ANTIGEN; MESSENGER RNA; RNA BINDING PROTEIN;

3' UNTRANSLATED REGION; ARTICLE; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOLECULAR CLONING; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; VASCULAR ENDOTHELIUM; BIOSYNTHESIS; CELL CULTURE; CYTOLOGY; GENETICS; HELA CELL; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; PROTEIN TRANSPORT; RNA PROCESSING; RNA STABILITY; TUMOR CELL LINE;

ANTIGENS, SURFACE; CELL LINE, TUMOR; CELLS, CULTURED; CHEMOKINE CX3CL1; ENDOTHELIUM, VASCULAR; HELA CELLS; HUMANS; INTERFERON-GAMMA; MOLECULAR SEQUENCE DATA; PROTEIN TRANSPORT; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA STABILITY; RNA, MESSENGER; RNA-BINDING PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77952753340     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903212     Document Type: Article

References (49)

1. Glass, C. K., and J. L. Witztum. 2001. Atherosclerosis. The road ahead. Cell 104: 503-516.
2. Young, J. L., P. Libby, and U. Schönbeck. 2002. Cytokines in the pathogenesis of atherosclerosis. Thromb. Haemost. 88: 554-567.
3. Harvey, E. J., and D. P. Ramji. 2005. Interferon-γ and atherosclerosis: pro- or anti-atherogenic? Cardiovasc. Res. 67: 11-20.
4. Kleemann, R., S. Zadelaar, and T. Kooistra. 2008. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc. Res. 79: 360-376.
5. Pennica, D., G. E. Nedwin, J. S. Hayflick, P. H. Seeburg, R. Derynck, M. A. Palladino, W. J. Kohr, B. B. Aggarwal, and D. V. Goeddel. 1984. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 312: 724-729. (Pubitemid 15195918)
6. Schroder, K., P. J. Hertzog, T. Ravasi, and D. A. Hume. 2004. Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75: 163-189.
7. Lusis, A. J. 2000. Atherosclerosis. Nature 407: 233-241.
8. Paludan, S. R. 2000. Synergistic action of pro-inflammatory agents: cellular and molecular aspects. J. Leukoc. Biol. 67: 18-25.
9. Bazan, J. F., K. B. Bacon, G. Hardiman, W. Wang, K. Soo, D. Rossi, D. R. Greaves, A. Zlotnik, and T. J. Schall. 1997. A new class of membrane-bound chemokine with a CX3C motif. Nature 385: 640-644.
10. Imai, T., K. Hieshima, C. Haskell, M. Baba, M. Nagira, M. Nishimura, M. Kakizaki, S. Takagi, H. Nomiyama, T. J. Schall, and O. Yoshie. 1997. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91: 521-530. (Pubitemid 27508241)
11. Teupser, D., S. Pavlides, M. Tan, J. C. Gutierrez-Ramos, R. Kolbeck, and J. L. Breslow. 2004. Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root. Proc. Natl. Acad. Sci. USA 101: 17795-17800.
12. Yoshida, H., T. Imaizumi, K. Fujimoto, N. Matsuo, K. Kimura, X. Cui, T. Matsumiya, K. Tanji, T. Shibata, W. Tamo, et al. 2001. Synergistic stimulation, by tumor necrosis factor-α and interferon-γ, of fractalkine expression in human astrocytes. Neurosci. Lett. 303: 132-136.
13. Fraticelli, P., M. Sironi, G. Bianchi, D. D'Ambrosio, C. Albanesi, A. Stoppacciaro, M. Chieppa, P. Allavena, L. Ruco, G. Girolomoni, et al. 2001. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J. Clin. Invest. 107: 1173-1181.
14. Sukkar, M. B., R. Issa, S. Xie, U. Oltmanns, R. Newton, and K. F. Chung. 2004. Fractalkine/CX3CL1 production by human airway smooth muscle cells: induction by IFN-γ and TNF-α and regulation by TGF-β and corticosteroids. Am. J. Physiol. Lung Cell. Mol. Physiol. 287: L1230-L1240.
15. Bhavsar, P. K., M. B. Sukkar, N. Khorasani, K. Y. Lee, and K. F. Chung. 2008. Glucocorticoid suppression of CX3CL1 (fractalkine) by reduced gene promoter recruitment of NF-kappaB. FASEB J. 22: 1807-1816.
16. Wong, G. H., and D. V. Goeddel. 1986. Tumour necrosis factors α and β inhibit virus replication and synergize with interferons. Nature 323: 819-822.
17. Meyer, R., E. N. Hatada, H. P. Hohmann, M. Haiker, C. Bartsch, U. Röthlisberger, H. W. Lahm, E. J. Schlaeger, A. P. van Loon, and C. Scheidereit. 1991. Cloning of the DNA-binding subunit of human nuclear factor k B: the level of its mRNA is strongly regulated by phorbol ester or tumor necrosis factor alpha. Proc. Natl. Acad. Sci. USA 88: 966-970.
18. Levy, D. E., D. J. Lew, T. Decker, D. S. Kessler, and J. E. Darnell, Jr. 1990. Synergistic interaction between interferon-α and interferon-γ through induced synthesis of one subunit of the transcription factor ISGF3. EMBO J. 9: 1105-1111. (Pubitemid 20110574)
19. Ohmori, Y., and T. A. Hamilton. 1995. The interferon-stimulated response element and a κ B site mediate synergistic induction of murine IP-10 gene transcription by IFN-γ and TNF-α. J. Immunol. 154: 5235-5244.
20. Qi, X. F., D. H. Kim, Y. S. Yoon, D. Jin, X. Z. Huang, J. H. Li, Y. K. Deung, and K. J. Lee. 2009. Essential involvement of cross-talk between IFN-γ and TNF-α in CXCL10 production in human THP-1 monocytes. J. Cell. Physiol. 220: 690-697.
21. Jahnke, A., and J. P. Johnson. 1994. Synergistic activation of intercellular adhesion molecule 1 (ICAM-1) by TNF-α and IFN-γ is mediated by p65/p50 and p65/c-Rel and interferon-responsive factor Stat1 α (p91) that can be activated by both IFN-γ and IFN-α. FEBS Lett. 354: 220-226.
22. Imanishi, D., K. Yamamoto, H. Tsushima, Y. Miyazaki, K. Kuriyama, M. Tomonaga, and T. Matsuyama. 2000. Identification of a novel cytokine response element in the human IFN regulatory factor-1 gene promoter. J. Immunol. 165: 3907-3916. (Pubitemid 32057299)
23. Winzen, R., M. Kracht, B. Ritter, A. Wilhelm, C. Y. Chen, A. B. Shyu, M. Müller, M. Gaestel, K. Resch, and H. Holtmann. 1999. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J. 18: 4969-4980. (Pubitemid 29443799)
24. Imaizumi, T., H. Itaya, K. Fujita, D. Kudoh, S. Kudoh, K. Mori, K. Fujimoto, T. Matsumiya, H. Yoshida, and K. Satoh. 2000. Expression of tumor necrosis factor-alpha in cultured human endothelial cells stimulated with lipopolysaccharide or interleukin-1alpha. Arterioscler. Thromb. Vasc. Biol. 20: 410-415.
25. Matsumiya, T., T. Imaizumi, H. Yoshida, K. Satoh, M. K. Topham, and D. M. Stafforini. 2009. The levels of retinoic acid-inducible gene I are regulated by heat shock protein 90-α. J. Immunol. 182: 2717-2725.
26. Dixon, D. A., C. D. Kaplan, T. M. McIntyre, G. A. Zimmerman, and S. M. Prescott. 2000. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3′-untranslated region. J. Biol. Chem. 275: 11750-11757.
27. Tenenbaum, S. A., P. J. Lager, C. C. Carson, and J. D. Keene. 2002. Ribonomics: identifying mRNA subsets in mRNP complexes using antibodies to RNAbinding proteins and genomic arrays. Methods 26: 191-198.
28. Chandrasekar, B., S. Mummidi, R. P. Perla, S. Bysani, N. O. Dulin, F. Liu, and P. C. Melby. 2003. Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway. Biochem. J. 373: 547-558. (Pubitemid 36897857)
29. Chen, Y. M., S. L. Lin, C. W. Chen, W. C. Chiang, T. J. Tsai, and B. S. Hsieh. 2003. Tumor necrosis factor-α stimulates fractalkine production by mesangial cells and regulates monocyte transmigration: down-regulation by cAMP. Kidney Int. 63: 474-486.
30. Warner, J. R., P. M. Knopf, and A. Rich. 1963. A multiple ribosomal structure in protein synthesis. Proc. Natl. Acad. Sci. USA 49: 122-129.
31. Hershey, J. W. 1991. Translational control in mammalian cells. Annu. Rev. Biochem. 60: 717-755.
32. Nelson, E. M., and M. M. Winkler. 1987. Regulation of mRNA entry into polysomes. Parameters affecting polysome size and the fraction of mRNA in polysomes. J. Biol. Chem. 262: 11501-11506.
33. Tobey, R. A., E. C. Anderson, and D. F. Petersen. 1966. RNA stability and protein synthesis in relation to the division of mammalian cells. Proc. Natl. Acad. Sci. USA 56: 1520-1527.
34. Fan, J., N. M. Heller, M. Gorospe, U. Atasoy, and C. Stellato. 2005. The role of post-transcriptional regulation in chemokine gene expression in inflammation and allergy. Eur. Respir. J. 26: 933-947.
35. Behm-Ansmant, I., I. Kashima, J. Rehwinkel, J. Saulière, N. Wittkopp, and E. Izaurralde. 2007. mRNA quality control: an ancient machinery recognizes and degrades mRNAs with nonsense codons. FEBS Lett. 581: 2845-2853. (Pubitemid 46874393)
36. von Roretz, C., and I. E. Gallouzi. 2008. Decoding ARE-mediated decay: is microRNA part of the equation? J. Cell Biol. 181: 189-194.
37. Zhang, T., V. Kruys, G. Huez, and C. Gueydan. 2002. AU-rich element-mediated translational control: complexity and multiple activities of trans-activating factors. Biochem. Soc. Trans. 30: 952-958.
38. Dean, J. L., G. Sully, A. R. Clark, and J. Saklatvala. 2004. The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation. Cell. Signal. 16: 1113-1121.
39. Beyaert, R., A. Cuenda, W. Vanden Berghe, S. Plaisance, J. C. Lee, G. Haegeman, P. Cohen, and W. Fiers. 1996. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J. 15: 1914-1923. (Pubitemid 26119694)
40. Birkenkamp, K. U., L. M. Tuyt, C. Lummen, A. T. Wierenga, W. Kruijer, and E. Vellenga. 2000. The p38 MAP kinase inhibitor SB203580 enhances nuclear factor-kappa B transcriptional activity by a non-specific effect upon the ERK pathway. Br. J. Pharmacol. 131: 99-107.
41. Subbaramaiah, K., T. P. Marmo, D. A. Dixon, and A. J. Dannenberg. 2003. Regulation of cyclooxgenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR. J. Biol. Chem. 278: 37637-37647.
42. Tran, H., M. Schilling, C. Wirbelauer, D. Hess, and Y. Nagamine. 2004. Facilitation of mRNA deadenylation and decay by the exosome-bound, DExH protein RHAU. Mol. Cell 13: 101-111. (Pubitemid 38117119)
43. Fan, X. C., and J. A. Steitz. 1998. Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAs. EMBO J. 17: 3448-3460.
44. Brennan, C. M., and J. A. Steitz. 2001. HuR and mRNA stability. Cell. Mol. Life Sci. 58: 266-277.
45. Cok, S. J., S. J. Acton, and A. R. Morrison. 2003. The proximal region of the 3′-untranslated region of cyclooxygenase-2 is recognized by a multimeric protein complex containing HuR, TIA-1, TIAR, and the heterogeneous nuclear ribonucleoprotein U. J. Biol. Chem. 278: 36157-36162.
46. Tran, H., F. Maurer, and Y. Nagamine. 2003. Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogen-activated protein kinase-activated protein kinase 2. Mol. Cell. Biol. 23: 7177-7188.
47. Lasa, M., K. R. Mahtani, A. Finch, G. Brewer, J. Saklatvala, and A. R. Clark. 2000. Regulation of cyclooxygenase 2 mRNA stability by the mitogen-activated protein kinase p38 signaling cascade. Mol. Cell. Biol. 20: 4265-4274.
48. Faure, E., L. Thomas, H. Xu, A. Medvedev, O. Equils, and M. Arditi. 2001. Bacterial lipopolysaccharide and IFN-γ induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-κ B activation. J. Immunol. 166: 2018-2024.
49. McCormick, C., and D. Ganem. 2005. The kaposin B protein of KSHV activates the p38/MK2 pathway and stabilizes cytokine mRNAs. Science 307: 739-741. (Pubitemid 40194646)